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CD4+Foxp3-expressing Treg cells, which constitu-
tively express the inhibitory coreceptor CTLA-4, are
indispensable for immune homeostasis. We deter-
mined the roles of Treg cells and T follicular regula-
tory (Tfr) cells in the control of humoral immune
responses. Depletion of Treg cells, blocking of
CTLA-4 or a Treg cell specific reduction in CTLA-4
expression, resulted in an increase in the formation
of antigen-specific Tfh cells, germinal center (GC),
and plasma and memory B cells after vaccination. In
the absence of Treg cell-expressed CTLA-4, large
numbers of Tfr cells were present but were unable
to restrain Tfh cell and GC formation. Temporary
Treg cell depletion during primary immunization was
sufficient to enhance secondary immune responses.
Tregcells directly inhibited, viaCTLA-4,Bcell expres-
sion of CD80 and CD86, which was essential for Tfh
cell formation. Thus, Treg and Tfr cells control Tfh
cell and germinal center development, via CTLA-4-
dependent regulation of CD80 and CD86 expression.
INTRODUCTION
Foxp3+regulatory T (Treg) cells constitute around 10%of periph-
eral CD4+ T cells and are crucial in the maintenance of immune
self-tolerance and homeostasis (Sakaguchi et al., 2008; Wing
and Sakaguchi, 2010). Loss of function of the transcription factor
Foxp3 in mice and humans causes widespread autoimmunity
and fatal lymphoproliferative disease (Bennett et al., 2001; Brun-
kow et al., 2001; Fontenot et al., 2003; Wildin et al., 2001; Wildin
et al., 2002), also displaying dysregulated humoral immunity
(Wing and Sakaguchi, 2014) characterized by large-scale spon-
taneous generation of germinal centers and T follicular helper
(Tfh) cells (Chung et al., 2011), and hyperproduction of immuno-
globulin E (IgE) (Lin et al., 2005; Wildin et al., 2002). It remains
obscure, however, how Treg cells control humoral immunity, in
particular whether they differentially control Th2 or Tfh, or directly
influence B cells, and what is the molecular basis of the control.
Tfh cells are specialized for the delivery of help to B cells within
the follicle (Crotty, 2011). In addition to the lineage defining tran-Immscription factor Bcl6, Tfh cells express the chemokine receptor
CXCR5,which in combinationwith a loss of CCR7 expression, al-
lows Tfh cells to travel into the B cell follicle and deliver help to B
cells, allowing maintenance of the germinal center reaction, gen-
eration of high-affinity antibody, and long-lasting plasma and
memory B cells (Crotty, 2011; Ma et al., 2012). More recently, it
has been demonstrated that a subset of Foxp3+ Treg cells gain
expression of Bcl6 and CXCR5, allowing their localization into
the B cell follicle where they control the expansion of the germinal
center and Tfh cells by as yet undefined mechanisms (Chung
et al., 2011; Linterman et al., 2011; Wollenberg et al., 2011).
Treg cells utilize a wide range of suppressive mechanisms
(Shevach, 2009; Yamaguchi et al., 2011). Yet, Treg-specific con-
ditional gene deletion (CKO) experiments have demonstrated
that CTLA-4 plays a dominant role in Treg cell maintenance of
immune self-tolerance and homeostasis as Treg cell CTLA-4
CKO mice suffer from hyper IgE, high concentrations of serum
IgG and autoantibodies, and lymphoproliferative disease, in
addition to fatal systemic autoimmunity, similar to Foxp3-defi-
cient mice (Wing et al., 2008). It remains to be determined, how-
ever, how CTLA-4 is involved in Treg cell-mediated suppression
of humoral immunity.
Here, we have investigated the role of Treg cells in the control
of the humoral response to foreign antigens, in particular how
they control antigen-specific Tfh and germinal center B cell re-
sponses. By in vivo depletion of Treg and T follicular regulatory
(Tfr) cells, Treg cell-specific deficiency of CTLA-4, or CTLA-4
blockade with specific antibodies, we have shown that Treg
and Tfr cells modulate humoral immunity to foreign antigens
via CTLA-4. In addition, Treg cell depletion either enhanced or
attenuated antigen-specific Tfh cell formation depending on
the timing and duration of Treg cell depletion. Thus, Treg and
Tfr cells control humoral immunity via CTLA-4, enabling thera-
peutic targeting of these cells, for example, in autoantibody-
mediated autoimmune diseases and IgE-mediated allergy.
RESULTS
Short-Term Depletion of Treg Cells Enhances Antigen-
Specific Tfh Cell Formation
Treg cell depletion was achieved by the DEREG depletion
system, in which Foxp3+ Treg cells express diphtheria toxin re-
ceptor (DTR) as part of a bacterial artificial chromosome (BAC)
transgene under the Foxp3 promoter (Lahl et al., 2007). DEREGunity 41, 1013–1025, December 18, 2014 ª2014 Elsevier Inc. 1013
Figure 1. Effect of Treg Depletion on T Follicular Helper Formation
(A and B) BALB/c DEREGmice were treated with 1 mg DT i.p. at days1, 3, 6, and 8, and vaccinated i.p. with 100 mg NP-Ova in Alum on day 0. (A) Time course of
Treg and Tfr depletion. (B) Effect of Treg depletion on Tfh (Bcl6+CXCR5+Foxp3) formation. n = 4 representative of four separate experiments.
(C–G) C57BL/6 Foxp3-DTR-GFP (FDG) mice were vaccinated i.p. with 50 mg NP-2W1S-GFP in alum at day 0. Mice were treated with DT on days 1,
3, 6, and 8 (DT long), DT at day 1 only (DT short) or PBS only (No DT), before analysis at day 10. Total 2W1S:I-Ab-PE tetramer-positive CD4+ T cells
from both spleen and lymph nodes were enumerated following anti-PE magnetic enrichment. (C) Foxp3 staining and GFP Foxp3 reporter at day 10. (D)
Tetramer staining pattern in unenriched and enriched samples, pregated on size, singlets, Live/Dead stainB220CD11cCD11bF4/80CD4+ cells.
(E) Representative staining patterns of tetramer+ (tet+) and tetramer (tet) CD4 T cells, Tfh identified as Bcl6+PD1+. (F) Total number of tet+ CD4+
(legend continued on next page)
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Role of Treg CTLA-4 in Humoral Immunitymice and wild-type (WT) littermates were treated with diphtheria
toxin (DT) on days 1, 3, 6, and 8 and vaccinated on day 0 with
ovalbumin (Ova) conjugated to the haptan 4-hydroxy-3-Nitro-
phenyl (NP). This led to a temporary loss of Treg cells, particu-
larly at the time of vaccination (Figure 1A). Although the total
Treg cell population rapidly recovered after DT treatment, we
found that the Tfr (CXCR5+Bcl6+Foxp3+) cell subset failed to
recover as late as 10 days after vaccination (Figure 1A). This de-
layed recovery of Tfr cells is likely due to the depletion of Treg
cells at the point of vaccination, when Treg cells presumably
receive the signals required to differentiate into Tfr cells, rather
than a more general loss of activated Treg cells, as CD103-ex-
pressing activated Treg cells were increased on day 10 post-
vaccination in DEREG mice (data not shown). After depletion
of Tregs, enhanced formation of Tfh cells expressing CXCR5,
Bcl6, and PD-1 was observed (Figure 1B) and, as might be ex-
pected from the loss of Tfr and gain of Tfh, the Tfh/Tfr ratio was
also significantly increased (data not shown). This enhanced Tfh
formation is likely to be at least partly due to the expansion of
autoreactive and polyclonal Tfh cell numbers since similar
expansion in numbers occurred with Treg cell depletion in the
absence of vaccination (data not shown). In addition, DEREG
mice showed a rapid reconstitution of Foxp3+ Tregs despite
repeated doses of DT (Figure 1A), due to expansion of an initially
small population of DTR-negative Treg cells (data not shown).
To address more precisely the kinetics of Treg cell depletion
on antigen-specific Tfh formation, we used another Treg DTR
model, which expressed a Foxp3-DTR-GFP (FDG) fusion pro-
tein (Kim et al., 2007). In FDG mice, a single treatment with
DT (DT short) 1 day before vaccination caused temporary deple-
tion of Treg cells and their reconstitution by day 10 while
repeated DT treatments (DT long) on days 1, 3, 6, and 8, sus-
tained the loss of Treg cells throughout the experiment (Fig-
ure 1C). In addition, FDG mice vaccinated with NP-2WIS-GFP
enabled assessment of MHCII 2W1S:I-Ab tetramer (tet)-binding
CD4+ T cells enriched by magnetic sorting (Moon et al., 2009)
(Figure 1D), allowing us to determine expansion of epitope-spe-
cific T cells in response to different timings of Treg cell deple-
tion. Because Bcl6+PD1+ is an accurate predictor of CXCR5
and BTLA positivity (data not shown), Tfh cells were identified
as Bcl6+PD1+ in tetramer experiments to avoid the interaction
between biotin-CXCR5:Streptavidin staining and biotinylated
tetramer. Interestingly, while both a single dose and repeated
doses of DT enhanced tet Tfh formation, repeated doses
clearly reduced the percentage of Tfh cells within the tet+ pop-
ulation (Figure 1E), suggesting that vaccine-specific Tfh cells
were being outcompeted by autoreactive Tfh cells. Correspond-
ingly, short-term Treg cell depletion increased total numbers of
tet+ Tfh and non-Tfh cells (Figure 1F), whereas sustained Treg
cell depletion significantly reduced the numbers of tet+ Tfh cells
(Figure 1G). We also confirmed that scaled doses of DT, and
consequently graded degrees of Treg cell depletion, exhibited
dose-dependent effects on Tfh cell formation, increased inter-
feron-g (IFN-g) and interleukin-4 (IL-4) production by Tfh cellsT cells following DT short schedule. Tfh = Bcl6+PD1+, PD1+Th = Bcl6PD
number of tetramer-positive (tet+) CD4+ T cells following repeated doses of D
and (B) from one-way ANOVA with Holm-Sidak multiple comparisons test co
mean + SEM. See also Figure S1.
Immin a similar manner to that previously observed in total CD4+
cells (Tian et al., 2011), and increased germinal center formation
by B cells (see Figure S1 available online). In contrast, Treg
depletion did not affect IL-21 expression by Tfh, although it
was increased in CXCR5 negative CD4 T cells (Figure S1). We
believe that the ratio of IL-4/IL-21 might be an important factor
in determining switching to IgE or IgG1 production. IL-17 pro-
duction was unaffected in both Tfh and non-Tfh (Figure S1).
Additionally, C57BL/6 DEREG mice enhanced tetramer-binding
Tfh cell numbers comparably to short-term DT-treated FDG
mice (Figure S1). Thus, transient Treg depletion and vaccination
together enhance antigen-specific Tfh cell formation.
Treg Cell Depletion Enhances Antigen-Specific B Cell
Responses
Treg cell depletion (DT treatment on days 1, 3, 6 and 8) in
BALB/c DEREG, NP-Ova-vaccinated mice increased the pro-
portion of NP-specific isotype class-switched (IgDIgM)
germinal center, plasma, and memory B cells when they were
vaccinated on day 0 and assessed on day 10 (Figures 2A and
B; Figure S2). NP-specific serum IgG2a and IgE, but not IgG1
and IgG3, antibody concentrations were also increased
concomitantly (Figure 2C). Using the FDG DTR depletion model
on the C57BL/6 background to investigate the kinetics, we found
that short-term Treg depletion (DT treatment on day 1) pro-
duced similar results to those seen in the DEREG mice; yet
sustained Treg depletion failed to increase the proportion of
antigen-specific GC B cells, although plasma cell levels were
enhanced (Figure S2). Serum concentrations of both total and
high-affinity anti-NP antibodies were increased in either condi-
tion, while anti-dsDNA antibody levels were enhanced by sus-
tained but not short-term depletion of Treg cells (Figure S2).
Additionally, the ratio of total antibody to high-affinity antibody
was not changed, suggesting that there was no significant effect
on affinity maturation (Figure S2). These experiments collectively
demonstrate that short-term depletion of Treg cells is both more
efficient at generating antigen-specific immunity and less likely
to generate autoimmunity. The observed effects of Treg cell
depletion were robust because similar results were observed
across different antigens (NP-Ova and NP-2WIS-GFP), mouse
strains (BALB/c and C57BL/6), and Treg cell depletion models
(DEREG BAC transgenic mice and FDG mice).
Memory Immunity Is Enhanced by Transient Treg Cell
Depletion
Because early memory B cells were increased at day 10 (Fig-
ure 2A), we sought to investigate whether this was translated
into long-term changes in immunological memory. Following a
similar DT and vaccination schedule to that used previously,
BALB/c mice were left until day 65 postprimary vaccination, re-
vaccinated without adjuvant, and analyzed 7 days later (Fig-
ure 3A). By this time point, Treg cell levels were not only fully
restored but were significantly, although slightly, higher in
DEREG than WT mice (Figure 3B). Tfr cells were reduced as1+, Th = Bcl6PD1, corresponding Treg subsets also Foxp3+. (G) Total
T (DT long). N = 7 pooled from two separate experiments. p values in (A)
mparing WT and DEREG at the indicated time points. Bars/lines represent
unity 41, 1013–1025, December 18, 2014 ª2014 Elsevier Inc. 1015
Figure 2. Effect of Treg Depletion on B Cell
Function
BALB/c DEREG mice were treated with 1 mg DT
I.P. at days1, 3, 6, and 8, and vaccinated i.p. with
100 mg NP-Ova in Alum on day 0. (A) Antigen-
specific (NP+) class switched (IgDIgM) germinal
center, plasma, and memory B cells at day 10
postvaccination. (B) Representative gating strat-
egy used to identify antigen-specific germinal
center B cells, pregated on size, singlets, dead cell
stain, B220+CD4 C) NP-specific serum anti-
body levels at day 10 postvaccination, determined
by NP(24)-BSA ELISA. p values in (C) from two-
way ANOVA. n = 4 representative of four separate
experiments. Bars/lines represent mean + SEM.
See also Figure S2.
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Role of Treg CTLA-4 in Humoral Immunitypercentage of Tfh (Figure 3B), but not total CD4+ T cells, resulting
in a significantly increased Tfh/Tfr ratio (data not shown), sug-
gesting that the initial loss of Tfr cells seen during primary vacci-
nation had not fully recovered. Class-switched NP-binding
germinal center B cells, plasma cells, and total Tfh cells were
also significantly enhanced in DEREG mice, suggesting that
the initial perturbation of Treg cells during primary vaccination
had lasting consequences on B and T cell memory responses
(Figure 3C). In addition, NP-binding total IgG and IgE levels
demonstrated an enhanced memory recall response in these
mice (Figure 3D). More detailed analysis of responding isotypes
revealed that similar to the primary response IgE and IgG2a
levels were increased, but in contrast to the primary response1016 Immunity 41, 1013–1025, December 18, 2014 ª2014 Elsevier Inc.IgG1 production was now also increased
(Figure S3). Similar to the primary
response, we did not see evidence of
significantly altered affinity maturation
as the ratio of total antibody to high-
affinity antibody was not changed
(Figure 3E).
Conditional Gene Deletion of Treg
Cell CTLA-4 Induces Spontaneous
Formation of Tfh Cells and
Germinal Centers
Given the critical role of Treg CTLA-4
expression in themaintenance of immune
homeostasis (Wing et al., 2008), it was
likely that the enhancement of humoral
immunity seen in the absence of Treg
and Tfr cells was primarily due to the
loss of CTLA-4-dependent Treg-sup-
pressive function. Tfr cells expressed
higher amounts of CTLA-4 in comparison
to the total Treg population (Figure 4A)
(Linterman et al., 2011). However, when
Tfr cells were compared to activated
CXCR5CD44+ Treg cells, we did not
see any clear difference in CTLA-4
expression levels (data not shown), indi-
cating that the enhanced CTLA-4 expres-
sion by Tfr cells might be a result of theiractivated status rather than an intrinsic difference from nonfollic-
ular resident Treg cells.
Previous reports havedemonstrated that anti-CTLA-4blocking
antibody enhances germinal center formation (Walker et al.,
2003), vaccine response inmacaques (Keler et al., 2003) andmu-
rine responses to polysaccharide vaccination (Boudewijns et al.,
2005). However, it has not been clearwhether CTLA-4 expressed
by Treg or effector T cells is responsible for this process since
effector Tcells alsopossesscell-extrinsicCTLA-4 function (Corse
and Allison, 2012; Ise et al., 2010; Wang et al., 2012). In order to
examine the specific contribution of Treg CTLA-4, we assessed
spontaneous germinal center formation and Tfh formation in
Treg-specific CTLA-4 CKO mice, which suffer from widespread
Figure 3. Treg Depletion during Primary
Vaccination Affects Long-Term Memory Re-
sponses
BALB/c DEREGmice were treated with 1 mg DT i.p.
at days 1, 3, 6, and 8, and vaccinated i.p. with
100 mg NP-Ova in Alum on day 0.65 days later.
Mice were revaccinated without any further DT
treatment or adjuvant and B and T cell responses
measured at day 7 postrevaccination.
(A) Outline of experiment.
(B) Proportions of Treg and Tfr at day 72.
(C) Germinal center and plasma NP specific
IgDIgM B cells and Tfh (CXCR5+Bcl6+) cells.
(D) Arbitrary units of NP-specific IgG and IgE at day
65 (prerevaccination), day 69 and day 72, deter-
mined by NP(30)-BSA ELISA.
(E) Ratios of arbitrary units of high affinity and total
NP binding antibody at day 72 as assessed by
binding to NP(4)-BSA and NP(30)-BSA, respec-
tively. p values in (D) from two-way ANOVA
comparing WT and DEREG mice. N = 6 pooled
from two separate experiments. Bars/lines repre-
sent mean + SEM. See also Figure S3.
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Role of Treg CTLA-4 in Humoral Immunityautoimmunity and splenomegaly in specific pathogen-free (SPF)
conditions, as we previously reported (Wing et al., 2008).
Comparing CTLA-4wt/wt, CTLA-4flox/wt, and CTLA-4flox/flox mice
(all Foxp3IRES-Cre+/Y hemizygous males), CTLA-4flox/wt heterozy-
gous mice exhibited a mild loss of CTLA-4 in both Treg and Tfr
cells compared to the profound loss of CTLA-4 expression seen
in CTLA-4flox/flox homozygous CKO mice (Figure 4A). Corre-
spondingly, CTLA-4flox/flox homozygous mice developed large
numbers of spontaneous germinal center B cells and Tfh cells in
the spleen; in addition, at sites where GC formation is normally
found inWTmicedue to interactionswithmicroflora (e.g., Peyer’s
patches andmesenteric lymphnode), GCand Tfh formationwere
also enhanced (Figures 4B and 4C). Interestingly, these mice
possessed high proportions of both Treg and Tfr cells (Figures
4D and 4E), a likely consequence of the large scale of inflamma-
tion. In contrast, CTLA-4flox/wt heterozygous mice did not suffer
from overt autoimmunity and had no clear induction of GCs and
Tfh in the spleen or mLN, with mild enhancement in the Peyer’s
patches (Figures 4A and 4B), and no clear expansion of Treg
cells (Figures 4C and 4D), suggesting that the reduced CTLA-4
expression in thesemicewas sufficient tomaintain self-tolerance
and homeostasis at least in the period we observed.
Thus, without CTLA-4, even high proportions of Treg and Tfr
cells are unable to restrain expansion of Tfh or GC formation,Immunity 41, 1013–1025, Desuggesting that other proposed mecha-
nisms of Treg and Tfr suppression of hu-
moral immunity are insufficient to retain
control in the absence of CTLA-4.
Treg CTLA-4 Controls Antigen-
Specific Tfh Formation and IL-4
Production
Upon vaccination, we found that CTLA-4
CKO mice had high levels of Tfh and
germinal center B cells, with very low
proportions of these cells displaying anti-gen specificity (data not shown). This again suggested that
outgrowth of autoreactive clones might outcompete the specific
response. However, because these mice suffered from wide-
spread inflammation and spontaneous formation of Tfh and
GC B cells, it was difficult to differentiate between the direct
effects of the loss of Treg CTLA-4 on vaccination and the more
indirect effects of inflammation. To address this point, we used
heterozygous CTLA-4flox/wt mice to examine specific immunity
(again in Foxp3IRES-Cre+/Y hemizygous males). As noted, these
mice failed to show clear spontaneous induction of Tfh and
GCs in the spleen and were essentially healthy at the observed
time points. We found that partial loss of CTLA-4 expression
led to increased splenic Tfh formation after vaccination (Fig-
ure 5A), in contrast to the lack of expansion seen in
the absence of vaccination (Figure 4C), suggesting that anti-
gen-specific Tfh formation was enhanced by reduction of
CTLA-4 expression. In addition, antigen-specific GC, plasma,
and memory B cells were increased while serum IgE, but not
IgG, levels were also raised (Figure 5B). To confirm the effect
of CTLA-4 on specific Tfh formation and IgE production, we
used CTLA-4 blocking antibody (Clone 9D9) (Quezada et al.,
2006) in C57BL/6 mice. We found that this caused the expansion
of total (non-tetramer stained) Tregs, Tfh, and Tfr, whereas the
Tfh/Tfr ratio was not significantly altered (Figure S4), suggestingcember 18, 2014 ª2014 Elsevier Inc. 1017
Figure 4. Spontaneous Formation of Tfh, Tfr, and Germinal Centers in CTLA-4 CKO Mice
Spontaneous generation of germinal centers, Tfh, Tregs, and Tfr in unvaccinated SPF BALB/c CTLA-4flox/flox, CTLA-4flox/wt, and CTLA-4wt/wt, Foxp3IRES-Cre mice
at 4 weeks of age. All mice are Foxp3IRES-Cre hemizygous males.
(A) Intracellular CTLA-4 expression by Tregs and Tfr in CTLA-4 floxed mice.
(B) Representative formation of GC, Tfh, and Tfr in spleen, mesenteric lymph nodes (mLN), and Peyer’s patches.
(C) Tfh formation in splenic CD4+.
(D) Percentage Treg in splenic CD4+.
(E) Percentage Tfr of splenic CD4+. Significance in (C), (D), and (E) from one-way ANOVAwith Holm-Sidak multiple comparisons test. n = 3 representative of three
separate experiments. Bars represent mean + SEM.
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Role of Treg CTLA-4 in Humoral Immunitythat, similar to the situation in CTLA-4 CKOmice, Tfr are present
but unable to exert suppression when CTLA-4 is blocked or ab-
sent. We then examined tetramer binding cells and found that,
similar to Treg depletion, CTLA-4 blocking induced significant
expansion of tetramer-binding PD1+Bcl6+ Tfh, PD1+Bcl6 acti-
vated T cells and PD1Bcl6 cells, thus enhancing both the per-
centage of tetramer-positive cells forming Tfh (Figure 5C) and the
total number of tetramer-positive cells (Figure 5D). Interestingly,
while tetramer-binding PD1Bcl6 Treg cells expanded in pro-
portion with PD1Bcl6 T cells, the numbers of tetramer-binding1018 Immunity 41, 1013–1025, December 18, 2014 ª2014 Elsevier InTfr cells were extremely low in the isotype-treated group and
failed to expand in a similar manner to Tfh (Figure 5D). This
suggested that anti-CTLA-4 antibody treatment preferentially
expanded tetramer-binding Tfh cells out of proportion with
their matching Tfr suppressive population, while PD1+ and
PD1Bcl6 Tregs were able to maintain a consistent ratio with
their matching effector populations (Figure S4). This is particu-
larly significant because the ratio of Tfh to Tfr might be more
important than their total numbers in determining the overall
strength of the humoral immune response (Sage et al., 2013).c.
Figure 5. Effect of CTLA-4 on Antigen Specific Tfh Cell Formation
(A and B) BALB/c CTLA4flox Foxp3IRES-Cre mice were vaccinated i.p. with 100 mg Np-Ova in Alum and analyzed at day 10. (A) Formation of Tfh, NP-specific
IgDIgM germinal center, plasma, and memory B cells in CTLA-4 heterozygous (flox/wt) and wild-type (wt/wt) mice. (B) NP-binding antibody from serum of
vaccinated mice, determined by NP(24)-BSA ELISA. n = 3 representative of three separate experiments. All mice in (A) and (B) are Foxp3IRES-Cre hemizygous
males.
(C–F) Human CD2 IL-4 reporter C57BL/6micewere treated i.p. with 500 mg anti-CTLA-4 (clone:9D9) or Isotype control 1 day prevaccination with 50 mgNP-2W1S-
GFP in alum then further treated with 250 mg antibody at days 2 and 5 before analysis at day 7. Total 2W1S:I-Ab-PE tetramer-positive CD4 T cells from combined
spleen and lymph nodes were enumerated following anti-PE magnetic enrichment. (C) Representative Bcl6 and PD1 staining pattern in antibody-treated
tetramer-positive (tet+) and tetramer-negative (tet) CD4+ T cells. (D) Total tet+ CD4 T cells per mouse, Tfh (Bcl6+PD1+), PD1+Th (Bcl6PD1+), and Th
(Bcl6PD1). Corresponding Treg subsets are also Foxp3+. (E) Representative cell-surface staining of human CD2 IL-4 reporter. (F) Total tet+, IL-4 positive, CD4
T cells per mouse. N = 6 pooled from two separate experiments. Bars/lines represent mean + SEM. p values in (B) are from two-way ANOVA comparing CTLA-4
floxed and WT mice. See also Figures S4 and S5.
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Role of Treg CTLA-4 in Humoral ImmunityIn addition to Tfh formation, CTLA-4 blockade significantly
enhanced NP-binding GC, plasma, and memory B cells and
the resulting antibody response on both C57BL/6 and BALB/c
backgrounds. Although the effect of CTLA-4 blocking on the
antibody response was specific to IgE on the BALB/c back-
ground, C57BL/6 also exhibited enhanced IgG formation, sug-
gesting some strain dependency of this effect (Figure S5). In
addition, by the use of an IL-4 reporter mouse system, we found
that the proportion of tet+ Tfh cells producing IL-4 was enhanced
following CTLA-4 blocking antibody treatment (Figure 5E) and
that this corresponded to a significant increase in the total
number of IL-4-producing, tetramer binding, Tfh cells (Figure 5F).
In combination with previous data that Treg cell depletion
enhanced IL-4 production by Tfh cells (Figure S1), this suggests
that Treg CTLA-4 might critically control IL-4 production by anti-
gen-specific Tfh cells and the resulting IgE response. In contrast,
the percentage of total Tfh cells expressing IFN-g was slightly
but significantly reduced, perhaps as a result of preferential con-
version to IL-4-positive Tfh cells (data not shown).
Treg Cell-Expressed CTLA-4 Controls B Cell CD80-
CD86 Expression and Tfh Formation
Tfh and Tfr cells require CD28-derived signaling in order to fully
commit to the Tfh or Tfr cell lineage as CD28 or B cell deficient or
depleted mice have reduced CD4+ T cell CXCR5 expression, Tfh
formation, and IL-4 production (Baumjohann et al., 2011; Haynes
et al., 2007; Leo´n et al., 2012; Linterman et al., 2011; Linterman
et al., 2009; Walker et al., 1999). B cell-specific expression of
CD86, but not CD80, is critical to the formation of Tfh cells in
the context of viral infection (Salek-Ardakani et al., 2011),
whereas loss of B cell CD80 expression has more subtle effects
on Tfh cell formation (Good-Jacobson et al., 2012). Because a
key effector function of Treg CTLA-4 is control of antigen-pre-
senting cell (APC) CD80 and 86 expression (Onishi et al., 2008;
Qureshi et al., 2011; Wing et al., 2008), it was a logical next
step to examine B cell CD80 and CD86 expression.
Depletion of Treg cells led to increased CD86 expressed by
both CD38+ naive and memory B cells and CD38 GC B cells
(Figures 6A and 6B), visible as early as day 3 after initial Treg
depletion. CD80 was significantly affected at a later time point
in CD38-positive B cells (Figure 6B). Additionally, B cell CD86
expression was increased following anti-CTLA-4 treatment or
in CTLA-4flox/wt, Foxp3IRES-Cre+/Y hemizygous male mice (Fig-
ure 6B). CD80 expression was significantly increased in GC B
cells following anti-CTLA-4 treatment, but not in CTLA-4 hetero-
zygous mice (data not shown). Dendritic cell (DC)-expressed
CD80 and 86 was also increased in a similar manner (data not
shown).
While it is already well established that Treg cells are able to
directly deplete CD80 and CD86 from DCs (Onishi et al., 2008;
Wing et al., 2008), it is less well defined whether they are able
to directly interact with B cells in the same way or whether the
effect on B cells seen in vivo is direct or a downstream conse-
quence of interactions with other cell types. In addition, although
Tfr cells are known to express CTLA-4, it is less clear whether
they are able to downregulate CD80 or CD86. To investigate
this issue, we used female mice homozygous for CTLA-4flox
but heterozygous for Foxp3IRES-Cre. Due to Foxp3 being en-
coded on the X chromosome, these mice have approximately1020 Immunity 41, 1013–1025, December 18, 2014 ª2014 Elsevier Inequal amounts of CTLA-4-sufficient and CTLA-4-deficient Treg
cells and are essentially healthy, allowing the purification of
CTLA-4-deficient Treg cells (marked by Cre-inducible RFP
expression by Rosa26 knockin of loxP-stop-loxP-RFP) without
the problems associated with purification of highly activated
Treg cells from full CTLA-4 CKO (Wing et al., 2008).
We found that, in vitro, both Treg and Tfr cells were able to
directly reduce B cell expression of CD80 and CD86 and that
this effect was reduced by the use of CTLA-4-deficient Treg or
Tfr cells (Figure 6C). Treg and Tfr cells were also able to effec-
tively prevent effector T cell proliferation when purified B cells
were used as stimulators and were similarly affected by the
loss of CTLA-4 (Figures 6D and 6E). This demonstrated that
Treg and Tfr cells shared similar suppressive mechanisms.
CTLA-4-deficient Tregs and Tfr exhibited significantly reduced,
but not a total loss of, suppressive function, suggesting that
CTLA-4-deficient Treg or Tfr cells might retain other suppressive
mechanisms in vitro, although this is not sufficient to prevent
in vivo autoimmunity (Shevach, 2009; Yamaguchi et al., 2011).
We also confirmed that Treg suppressive function on B cells
was efficiently blockable by anti-CTLA-4 Fab (Figure S6) and
that the Treg/Tfr-dependent depletion of CD80 and CD86 was
specific as other factors such as CD40, MHC-II, and CD69
expression and B cell proliferation were not affected by Treg
cells (Figure S6). Conversely, B cell CD25 expression was slightly
enhanced by the addition of Treg cells; the mechanism for this is
as yet unknown but might conceivably affect IL-2 availability.
Role of B Cell-Specific Expression of CD80 and 86 in Tfh
Formation
To further probe the role of CD80 and CD86 in Tfh formation, we
investigated the formation of Tfh and germinal center B cells in
CD80- and CD86-deficient mice. As expected,Cd80/Cd86/
mice were deficient in the Tfh cells that normally form in the
Peyer’s patches (Figure 7A). In order to confirm the role of B
cell-specific CD80 andCD86 expression, we used transfer of
WT CD45.1 B cells into Cd80/Cd86/ recipients and found
that transfer of CD80- and CD86-expressing B cells alone was
sufficient to induce the formation of Tfh cells as measured as
either Bcl6+CXCR5+ or Bcl6+PD1+ cells, whereas transfer of
the same number of Cd80/Cd86/ B cells had no effect (Fig-
ure 7B). While the numbers of Tfh cells were low, probably due to
the relatively small number of WT B cells that were able to suc-
cessfully implant into nonlymphopenic mice, Tfh formation was
significantly increased (Figure 7C). This is in agreement with
previous findings and demonstrates that this mechanism is not
specific to viral infection (Salek-Ardakani et al., 2011). We also
observed that CD45.1+ WT donor cells formed germinal centers
and expressed Bcl6, whereasCd80/Cd86/ host B cells cells
did not, suggesting that B cells have some cell-intrinsic depen-
dency on their expression of CD80 and CD86 in order to differen-
tiate into germinal center B cells (Figures 7D and E).
DISCUSSION
The role of Treg and Tfr cells in the control of the immune
response to foreign antigens has proven controversial (Wing
and Sakaguchi, 2014). Previous studies examining depletion of
total Treg cells have reported that Treg depletion might (Eddahric.
Figure 6. CTLA-4 Dependent Treg Control
of B Cell CD80 and CD86 Expression
(A) BALB/c DEREGmice were treated with 1 mg DT
i.p. at days1, 3, 6, and 8, and vaccinated i.p. with
100 mg NP-Ova in Alum at day 0. Time course of B
cell CD86 expression following Treg depletion.
(B) CD86 and CD80 expression on both CD38-
negative (germinal center) and CD38-positive
(naive/memory) B cells at day 10 after initial Treg
depletion (DEREG), or in CTLA-4flox/wt heterozy-
gous FIC hemizygous male mice, or 7 days after
initial anti-CTLA-4 treatment. n = 4 representative
of three (DEREG) or two (anti-CTLA-4, CTLA-4flox)
separate experiments.
(C and D) Tregs and Tfr were isolated from female
BALB/c CTLA-4flox/flox, Foxp3Cre ±, Rosa-RFP (Cre
reporter)mice.RFP+CTLA-4KOTreg/TfrandRFP
CTLA-4 sufficient Tregs/Tfr were purified by FACS
ARIA-II on the basis of CD25 and GITR positivity or
CD25, GITR, CXCR5, and PD1 positivity respec-
tively. (C) Effect of Treg/Tfr CTLA-4 on B cell
expression of CD80/86. Purified splenic CD19+ B
cells (1 3 104) were incubated at a 2:1 ratio with/
without CTLA-4 KO or WT Tregs or Tfr and 10 mg
anti-igM, 10 mg anti-CD40, 20IU IL-2, and 0.5 mg
anti-CD3 and for 3 days before assessment of
CD80 andCD86expressiononB220-positive cells.
Numbers on histograms show MFI (median fluo-
rescence index). (D) CD4+CD25 T cell (Th) prolif-
eration. CFSE-stained CD4+CD25 cells (5 3 103)
were incubated with anti-CD3 and a 1:2 ratio of live
Bcells in thepresence/absenceofdifferent ratiosof
Tregs or Tfr for 3 days. T cell proliferation assessed
by CFSE dilution. Number on histograms repre-
sents percentage of divided cells.
(E) Dose dependence of Treg to Th ratio. Repre-
sentative of two separate experiments carried
out in duplicate. p values in (A) are from two-way
ANOVA comparing DEREG and WT mice. Bars/
lines represent mean + SEM. See also Figure S6.
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Role of Treg CTLA-4 in Humoral Immunityet al., 2006) or might not (Leo´n et al., 2014; Ludwig-Portugall
et al., 2009; Ludwig-Portugall et al., 2008; Morgan et al., 2003)
enhance responses to foreign antigens. This is also the case
with Tfr cells with both enhancement (Chung et al., 2011; Liu
et al., 2014; Vaeth et al., 2014; Wollenberg et al., 2011) and inhi-
bition (Linterman et al., 2011) of specific immune responses
observed in models evaluating the effects of Treg cell-specific
loss of the critical Tfr differentiation or localization factors such
as Bcl6, CXCR5, or SAP.
We have found that temporary depletion of Treg cells leads to
enhanced primary and secondary vaccine responses but that
longer-term depletion of Treg cells reduced the total number of
epitope-specific Tfh cells, despite an overall increase in Tfh cells.
Additionally, we observed that in either long-term Treg-depleted
mice or CTLA-4 CKO mice, the percentage of the proportion
of antigen-specific B cells within themwere reduced, while over-
all proportions of germinal centers increased. It is likely thatImmunity 41, 1013–1025, Dealthough short-term depletion of Treg
cells might enhance availability of costi-
mulatory molecules such as CD80 and
CD86, enhancing antigen-specific Tfhformation, more prolonged absence of Tregs leads to a loss of
immune homeostasis and uncontrolled expansion of nonspecific
and polyclonal Tfh and B cells, which might outcompete the an-
tigen-specific response. This suggests that Treg cells play a
finely balanced role: while antigen-specific Treg cells might sup-
press the relevant response, polyclonal Treg cells are critical for
the maintenance of immune homeostasis. Interestingly, in the
setting of mucosal immunity, transfer of antigen-specific Treg
cells suppress, whereas polyclonal Treg cells enhance specific
antibody production (Vendetti et al., 2010). In addition, different
schedules of DT treatment in DEREG mice appear to either
reduce or have no effect on the avidity of responding tetramer-
positive CD8 cells (Pace et al., 2012). Attempts to modify Treg
function in order to enhance vaccination against foreign or self
(or tumor) antigens must consider that the timing and duration
of Treg depletion might be critical to the outcome with the pos-
sibility that prolonged polyclonal depletion of Treg cells mightcember 18, 2014 ª2014 Elsevier Inc. 1021
Figure 7. B Cell-Specific Role for CD80/86 in Tfh and GC Formation
(A) Tfh formation in the Peyer’s patches of WT and Cd80/Cd86/ mice. Representative of three separate experiments.
(B–E) CD19+ B cells (1 3 107) isolated from CD45.1 mice were transferred intravenously into Cd80/Cd86/ mice, which were vaccinated the next day with
100 mg NP-Ova, and analyzed at day 10 postvaccination. (B) Representative data and (C) summary of Tfh formation in recipient mice. (D) Germinal center B cell
formation in recipient mice and GC formation by transferred WT B cells in Cd80/Cd86/ mice. n = 3 representative of two separate experiments. Bars
represent mean + SEM.
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Role of Treg CTLA-4 in Humoral Immunitycause a loss of immune homeostasis detrimental to the desired
antigen-specific immune response.
The Treg depletion mechanism used in this study does not
differentiate between the contribution of Treg cells and follicular
resident Tfr cells, although we found that Tfr cells appear to be
slower to recover from short-term Treg depletion. Because the
effect of Treg depletion on B cell CD86 expression was visible
as early as day 3 post-Treg depletion, a time point prior to the for-
mation of significant numbers of Tfr, it seems likely that follicular
nonresident Treg cells exert early CTLA-4-dependent control of
CD86 expression, which allows them to affect the initiation of Tfh
and germinal center formation while Tfr cells act at a later stage,
controlling the expansion and resolution of already formed
germinal centers. Because Treg cells are the source of Tfr cells,
the line between them is likely to be blurred because Tfr precur-
sor Treg cells might exert suppressive function on the DCs and
cognate B cells required for their conversion to Tfr cells, which
prevent the APCs from assisting Tfh formation. The exact divi-
sion of labor between Treg cells, other than as a source of Tfr
cells, and bona fide Tfr cells to control humoral immunity is a
question that must be addressed in future studies.
Despite possible contributions of a number of mechanisms by
which Tregs/Tfr suppress humoral immunity, we have shown
that in the absence of CTLA-4, other potential Treg and Tfr-sup-
pressive mechanisms, such as production of IL-10 or transform-
ing growth factor-b (Linterman et al., 2011), are not sufficient to
control GC formation, suggesting that theymight have a second-
ary role in fine-tuning the response (Yamaguchi et al., 2011).
Potentially, CTLA-4 blocking might prove more efficient than
Treg depletion in generating antigen-specific Tfh as it removes
the key Treg suppressive function while still providing some con-
trol over IL-2 availability that might otherwise suppress Tfh for-
mation (Leo´n et al., 2014). However, it is clear from widespread
Tfh formation in scurfy mice that in the absence of Treg cells,
high IL-2 availability is not able to totally prevent Tfh formation
(Chung et al., 2011).
Previous reports have identified that IL-4 produced by Th2
cells is particularly sensitive to either Treg depletion or total
loss of CTLA-4 expression in full CTLA-4 KO mice (Bour-Jordan
et al., 2003; Tian et al., 2011), suggesting that IL-4 produced by
Th2 cells might drive IgE production. However, more recently, it
has become clear that Tfh cells might be the primary T cell type
driving antibody production (Reinhardt et al., 2009) and are
capable of producing IL-4 (King and Mohrs, 2009). Furthermore,
loss of IL-4 production by Th2 cells has been observed to have
little effect on IgE while a selective deficiency of Tfh IL-4 produc-
tion profoundly inhibits IgE production (Harada et al., 2012;
Vijayanand et al., 2012). We have observed that Tfh cells from
Treg-depleted mice produce high levels of IL-4 and that IL-4
production by antigen-specific Tfh is enhanced by CTLA-4
blockade. This leads us to suggest that while both Th2 and Tfh
cells secrete IL-4 in the absence of Treg cells, Tfh-derived IL-4
might be a critical factor in the hyper IgE observed in Treg-
depleted or CTLA-4-impaired mice because of their follicular
localization. Interestingly, anti-CTLA-4 antibodies have also
been used in several infection models: protection is observed
against the helminth Nippostrongylus brasiliensis (McCoy et al.,
1997), but not Mycobacterium bovis (Kirman et al., 1999). It
seems likely the effect of CTLA-4 blocking on IL-4 productionImmby antigen-specific Tfh and the resultant IgE responses might
explain the sensitivity of helminth infections to anti-CTLA-4
treatment.
In conclusion, we have found that Treg cells, via CTLA-4,
modulate Tfh formation and consequently primary and second-
ary B cell responses. The loss of control of both Tfh and GC
formation in the Treg CTLA-4 CKO mouse demonstrates that in
the absence of CTLA-4 expression, Tregs and Tfr are unable to
restrain the germinal center reaction and Tfh formation. As
such, we believe that CTLA-4-dependent suppression is the pri-
mary mechanism used by Treg and Tfr cells to control humoral
immunity and might be particularly critical in the control of anti-
gen-specific IgE formation.
EXPERIMENTAL PROCEDURES
Mice
BALB/c and C57BL/6 mice were obtained from CLEA Japan and maintained
under specific pathogen-free conditions.
BAC transgenic Foxp3 DTR (DEREG), Foxp3 fusion protein DTR-GFP (FDG),
CTLA-4flox, Cd80/Cd86/, Foxp3IRES-Cre, Rosa-RFP Cre reporter, and
hCD2-IL4 reporter mice have already been described (Harada et al., 2012;
Kim et al., 2007; Lahl et al., 2007; Wing et al., 2008).
Experiments were conducted with mice of at least 6 weeks of age, except
where noted, and were conducted in compliance with Osaka University
regulations.
Vaccinations
Mice were vaccinated intraperitoneally with 100 mg NP-Ova or 50 mg NP-
2W1S-GFP mixed with 100 ml Imject alum (Pierce) in a total volume of 200 ml
on day 0 of each experiment.
DT receptor-expressing mice were depleted of Tregs by intraperitoneal (i.p.)
injection of 1 mg of DT (MerckMillipore) 1 day prevaccination and days 3, 6, and
8 postvaccination unless otherwise stated. Mice were analyzed at 10 days
postvaccination. In vivo CTLA-4 blocking was achieved by i.p. injection of
mice with 500 mg CTLA-4 blocking antibodies (clone 9D9: hybridoma, a kind
gift of James Allison) or isotype control (Clone MPC-11: BioXcell) on day 1
followed by 250 mg on days 3 and 5.
Flow Cytometry and Antibodies
Cells were stained at 4C for 30 min (1 hr at 37C for CXCR5 biotin). Intracel-
lular cytokine staining was carried out following incubation of cells with 50 ng
PMA, 500 ng Ionomycin, and 1/1000 GolgiStop (BD) for 4 hr 37C. Intracellular
staining was carried out by eBioscence intracellular staining kit according to
the manufacturer’s instructions. Antibody clones are listed in the Supple-
mental Experimental Procedures. Samples were collected on an LSR Fortessa
(BD) and compensation and data analysis was carried out with FlowJo vX.0.7
(Treestar).
MHC-II Tetramer Assay
Tetramer binding T cells were identified using 2W1S peptide: MHC-II I-Ab
tetramer as described previously (Moon et al., 2009;Moon et al., 2007). Briefly,
epitope-specific T cells were detected by incubation with 2W1S:I-Ab PE-con-
jugated tetramer (a kind gift from Marc Jenkins) for 1 hr at room temperature.
Cells were then washed twice before incubation with anti-PE microbeads (Mil-
tenyi Biotech) at 4C for 30 min followed by two further washes and then
enrichment by Midi MACS LS column (Miltenyi Biotech). The enriched and
depleted fractions were then stained and run on a BD LSR Fortessa cytometer
as described above. Tetramer-positive T cells were identified as Live/Dead
stainB220CD11cCD11bF4/80CD4+ cells.
ELISA
Serum samples from mice were collected by tail vein or cardiac puncture (for
terminal blood sample collection) and assessed for NP-specific antibodies
by ELISA. BSA-NP26, or BSA-NP4 (2 mg/ml: Biosearch) or 100 mg/ml, 45 mm
filtered, dsDNA from salmon sperm (Biodynamics) was used to captureunity 41, 1013–1025, December 18, 2014 ª2014 Elsevier Inc. 1023
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Role of Treg CTLA-4 in Humoral Immunityantibody either total or high-affinity antibody and anti-igG, IgG1, IgG2a, IgG2b,
IgG2c, IgG3, or IgE-HRP (Southern Biotech) were used as secondary anti-
bodies. Arbitrary units were calculated by comparison with pooled samples
from vaccinatedmice. Total/high-affinity antibody ratioswere calculated by di-
vision of arbitrary units from ELISA with BSA-NP-30 and BSA-NP4 used as
capture reagents. A TMBSubstrate Reagent Set (BD) was used before reading
at 450 nm.
Cell Isolation and Sorting
Tregs were isolated from the spleens of BALB/cmice based on one expression
of CD4 CD25 and GITR, and Tfr were isolated as CD4+B220CXCR5+PD1+
CD25+GITR+ using a FACS ARIA II cell sorter (BD). B cells were isolated by
positive selection with anti-CD19 magnetic beads via a MidiMACS system
(Miltenyi Biotech) according to manufacturer’s instructions.
Cell Transfer Experiments
CD19+ B cells (13 107) were isolated fromCD45.1mice were transferred intra-
venously into CD80/86KO mice 1 day before vaccination. At day 0, mice were
vaccinated with 100 mg NP-Ova. Mice were then analyzed at day 10 postvac-
cination and cells were assessed by flow cytometry.
In Vitro Proliferation and Activation-Marker Expression
B cells were incubated with Tregs in the presence of 12.5 mg/ml LPS or 10 mg/
ml anti-igM and 10 mg/ml anti-CD40 and, 0.5 mg/ml anti-CD3, and 20/IU IL-2 to
activate and maintain Treg function. B cell activation marker expression was
assessed by flow cytometry following 3 days of incubation in RPMI media at
37C 5% CO2.
T cell proliferation was assessed by addition of FACS Aria sorted CD4+
CD25 T effector cells stained with 5 mM CFSE at a 1:1:2 ratio with CD4+
CD25+GITR+ Tregs, CD4+CD25+CXCR5+PD1+ Tfr, and CD19+ B cells as
APCs. Anti-CD3 was also added to provide T cell stimulation. Proliferation
was assessed following 3 days of incubation at 37C.
In vitro blocking of CTLA-4 function was achieved by addition of CTLA-4 Fab
fragments, at the indicated concentrations, made by digesting UC10 anti-
CTLA-4 antibody with the Pierce Fab preparation kit (Pierce) according to
manufacturer’s instructions.
Statistics
Comparisons between groups were calculated by unpaired Student’s t test
unless otherwise stated. *p % 0.05 **p % 0.01 ***p % 0.001 ****p % 0.0001.
All statistics were calculated by GraphPad Prism V6.02 (GraphPad Software).
SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures and Supplemental Experimental
Procedures and can be found with this article online at http://dx.doi.org/10.
1016/j.immuni.2014.12.006.
AUTHOR CONTRIBUTIONS
J.B.W. designed experiments, performed experiments, analyzed data, and
wrote the manuscript. W.I. and T.K. designed experiments. S.S. supervised
the study and wrote the manuscript.
ACKNOWLEDGMENTS
J.B.W. is the recipient of a Japan Society for the Promotion of Science young
scientist B grant (25860356), S.S. is the recipient of Grants-in-Aid for Specially
Promoted Research (20002007) and for Scientific Research (A) (26253030)
from the Ministry of Education, Culture, Sports, Science and Technology of
Japan; Core Research for Evolutional Science and Technology (CREST)
from Japan Science and Technology Agency; W.I. and T.K. were supported
by grants from the Ministry of Education, Culture, Sports, Science, and Tech-
nology in Japan and by a CREST grant to T.K. We would like to thank M. Jen-
kins for kindly providing 2W1S:I-Ab tetramer, T. Sparwasser for provision of the
DEREGmouse strain, M. Kubo for provision of hCD2-IL-4 reporter mice, J. Al-
lison for provision of the 9D9 hybridoma, H. Nishikawa, D. Sugiyama, H. Hume
and D. Adgeebe for helpful discussions, and H. Run for technical support.1024 Immunity 41, 1013–1025, December 18, 2014 ª2014 Elsevier InReceived: May 30, 2014
Accepted: October 31, 2014
Published: December 18, 2014
REFERENCES
Baumjohann, D., Okada, T., and Ansel, K.M. (2011). Cutting Edge: Distinct
waves of BCL6 expression during T follicular helper cell development.
J. Immunol. 187, 2089–2092.
Bennett, C.L., Christie, J., Ramsdell, F., Brunkow, M.E., Ferguson, P.J.,
Whitesell, L., Kelly, T.E., Saulsbury, F.T., Chance, P.F., and Ochs, H.D.
(2001). The immune dysregulation, polyendocrinopathy, enteropathy, X-linked
syndrome (IPEX) is caused by mutations of FOXP3. Nat. Genet. 27, 20–21.
Boudewijns, M., Jeurissen, A., Wuyts, M., Moens, L., Boon, L., Van Neerven,
J.J., Kasran, A., Overbergh, L., Lenaerts, C., Waer, M., et al. (2005).
Blockade of CTLA-4 (CD152) enhances themurine antibody response to pneu-
mococcal capsular polysaccharides. J. Leukoc. Biol. 78, 1060–1069.
Bour-Jordan, H., Grogan, J.L., Tang, Q., Auger, J.A., Locksley, R.M., and
Bluestone, J.A. (2003). CTLA-4 regulates the requirement for cytokine-induced
signals in T(H)2 lineage commitment. Nat. Immunol. 4, 182–188.
Brunkow, M.E., Jeffery, E.W., Hjerrild, K.A., Paeper, B., Clark, L.B., Yasayko,
S.A., Wilkinson, J.E., Galas, D., Ziegler, S.F., and Ramsdell, F. (2001).
Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal
lymphoproliferative disorder of the scurfy mouse. Nat. Genet. 27, 68–73.
Chung, Y., Tanaka, S., Chu, F., Nurieva, R.I., Martinez, G.J., Rawal, S., Wang,
Y.H., Lim, H., Reynolds, J.M., Zhou, X.H., et al. (2011). Follicular regulatory
T cells expressing Foxp3 and Bcl-6 suppress germinal center reactions. Nat.
Med. 17, 983–988.
Corse, E., and Allison, J.P. (2012). Cutting edge: CTLA-4 on effector T cells in-
hibits in trans. J. Immunol. 189, 1123–1127.
Crotty, S. (2011). Follicular helper CD4 T cells (TFH). Annu. Rev. Immunol. 29,
621–663.
Eddahri, F., Oldenhove, G., Denanglaire, S., Urbain, J., Leo, O., and Andris, F.
(2006). CD4+ CD25+ regulatory T cells control the magnitude of T-dependent
humoral immune responses to exogenous antigens. Eur. J. Immunol. 36,
855–863.
Fontenot, J.D., Gavin, M.A., and Rudensky, A.Y. (2003). Foxp3 programs the
development and function of CD4+CD25+ regulatory T cells. Nat. Immunol.
4, 330–336.
Good-Jacobson, K.L., Song, E., Anderson, S., Sharpe, A.H., and Shlomchik,
M.J. (2012). CD80 expression on B cells regulates murine T follicular helper
development, germinal center B cell survival, and plasma cell generation.
J. Immunol. 188, 4217–4225.
Harada, Y., Tanaka, S., Motomura, Y., Harada, Y., Ohno, S., Ohno, S., Yanagi,
Y., Inoue, H., and Kubo, M. (2012). The 30 enhancer CNS2 is a critical regulator
of interleukin-4-mediated humoral immunity in follicular helper T cells.
Immunity 36, 188–200.
Haynes, N.M., Allen, C.D., Lesley, R., Ansel, K.M., Killeen, N., and Cyster, J.G.
(2007). Role of CXCR5 and CCR7 in follicular Th cell positioning and appear-
ance of a programmed cell death gene-1high germinal center-associated sub-
population. J. Immunol. 179, 5099–5108.
Ise,W., Kohyama,M., Nutsch, K.M., Lee, H.M., Suri, A., Unanue, E.R., Murphy,
T.L., and Murphy, K.M. (2010). CTLA-4 suppresses the pathogenicity of self
antigen-specific T cells by cell-intrinsic and cell-extrinsic mechanisms. Nat.
Immunol. 11, 129–135.
Keler, T., Halk, E., Vitale, L., O’Neill, T., Blanset, D., Lee, S., Srinivasan, M.,
Graziano, R.F., Davis, T., Lonberg, N., and Korman, A. (2003). Activity and
safety of CTLA-4 blockade combinedwith vaccines in cynomolgusmacaques.
J. Immunol. 171, 6251–6259.
Kim, J.M., Rasmussen, J.P., and Rudensky, A.Y. (2007). Regulatory T cells
prevent catastrophic autoimmunity throughout the lifespan of mice. Nat.
Immunol. 8, 191–197.
King, I.L., andMohrs, M. (2009). IL-4-producing CD4+ T cells in reactive lymph
nodes during helminth infection are T follicular helper cells. J. Exp. Med. 206,
1001–1007.c.
Immunity
Role of Treg CTLA-4 in Humoral ImmunityKirman, J., McCoy, K., Hook, S., Prout, M., Delahunt, B., Orme, I., Frank, A.,
and Le Gros, G. (1999). CTLA-4 blockade enhances the immune response
induced by mycobacterial infection but does not lead to increased protection.
Infect. Immun. 67, 3786–3792.
Lahl, K., Loddenkemper, C., Drouin, C., Freyer, J., Arnason, J., Eberl, G.,
Hamann, A., Wagner, H., Huehn, J., and Sparwasser, T. (2007). Selective
depletion of Foxp3+ regulatory T cells induces a scurfy-like disease. J. Exp.
Med. 204, 57–63.
Leo´n, B., Ballesteros-Tato, A., Browning, J.L., Dunn, R., Randall, T.D., and
Lund, F.E. (2012). Regulation of T(H)2 development by CXCR5+ dendritic cells
and lymphotoxin-expressing B cells. Nat. Immunol. 13, 681–690.
Leo´n, B., Bradley, J.E., Lund, F.E., Randall, T.D., and Ballesteros-Tato, A.
(2014). FoxP3+ regulatory T cells promote influenza-specific Tfh responses
by controlling IL-2 availability. Nat Commun 5, 3495.
Lin, W., Truong, N., Grossman, W.J., Haribhai, D., Williams, C.B., Wang, J.,
Martı´n, M.G., and Chatila, T.A. (2005). Allergic dysregulation and hyperimmu-
noglobulinemia E in Foxp3 mutant mice. J. Allergy Clin. Immunol. 116, 1106–
1115.
Linterman, M.A., Rigby, R.J., Wong, R.K., Yu, D., Brink, R., Cannons, J.L.,
Schwartzberg, P.L., Cook, M.C., Walters, G.D., and Vinuesa, C.G. (2009).
Follicular helper T cells are required for systemic autoimmunity. J. Exp. Med.
206, 561–576.
Linterman, M.A., Pierson, W., Lee, S.K., Kallies, A., Kawamoto, S., Rayner,
T.F., Srivastava, M., Divekar, D.P., Beaton, L., Hogan, J.J., et al. (2011).
Foxp3+ follicular regulatory T cells control the germinal center response.
Nat. Med. 17, 975–982.
Liu, X., Chen, X., Zhong, B., Wang, A., Wang, X., Chu, F., Nurieva, R.I., Yan, X.,
Chen, P., van der Flier, L.G., et al. (2014). Transcription factor achaete-scute ho-
mologue 2 initiates follicular T-helper-cell development. Nature 507, 513–518.
Ludwig-Portugall, I., Hamilton-Williams, E.E., Gottschalk, C., and Kurts, C.
(2008). Cutting edge: CD25+ regulatory T cells prevent expansion and induce
apoptosis of B cells specific for tissue autoantigens. J. Immunol. 181, 4447–
4451.
Ludwig-Portugall, I., Hamilton-Williams, E.E., Gotot, J., and Kurts, C. (2009).
CD25+ T(reg) specifically suppress auto-Ab generation against pancreatic tis-
sue autoantigens. Eur. J. Immunol. 39, 225–233.
Ma, C.S., Deenick, E.K., Batten, M., and Tangye, S.G. (2012). The origins,
function, and regulation of T follicular helper cells. J. Exp.Med. 209, 1241–1253.
McCoy, K., Camberis, M., and Gros, G.L. (1997). Protective immunity to
nematode infection is induced byCTLA-4 blockade. J. Exp.Med. 186, 183–187.
Moon, J.J., Chu, H.H., Pepper, M., McSorley, S.J., Jameson, S.C., Kedl, R.M.,
and Jenkins, M.K. (2007). Naive CD4(+) T cell frequency varies for different epi-
topes and predicts repertoire diversity and response magnitude. Immunity 27,
203–213.
Moon, J.J., Chu, H.H., Hataye, J., Paga´n, A.J., Pepper, M., McLachlan, J.B.,
Zell, T., and Jenkins, M.K. (2009). Tracking epitope-specific T cells. Nat.
Protoc. 4, 565–581.
Morgan, M.E., Sutmuller, R.P., Witteveen, H.J., van Duivenvoorde, L.M.,
Zanelli, E., Melief, C.J., Snijders, A., Offringa, R., de Vries, R.R., and Toes,
R.E. (2003). CD25+ cell depletion hastens the onset of severe disease in
collagen-induced arthritis. Arthritis Rheum. 48, 1452–1460.
Onishi, Y., Fehervari, Z., Yamaguchi, T., and Sakaguchi, S. (2008). Foxp3+ nat-
ural regulatory T cells preferentially form aggregates on dendritic cells in vitro
and actively inhibit their maturation. Proc. Natl. Acad. Sci. USA 105, 10113–
10118.
Pace, L., Tempez, A., Arnold-Schrauf, C., Lemaitre, F., Bousso, P., Fetler, L.,
Sparwasser, T., andAmigorena,S. (2012).RegulatoryT cells increase theavidity
of primary CD8+ T cell responses and promotememory. Science 338, 532–536.
Quezada, S.A., Peggs, K.S., Curran, M.A., and Allison, J.P. (2006). CTLA4
blockade and GM-CSF combination immunotherapy alters the intratumor bal-
ance of effector and regulatory T cells. J. Clin. Invest. 116, 1935–1945.
Qureshi, O.S., Zheng, Y., Nakamura, K., Attridge, K., Manzotti, C., Schmidt,
E.M., Baker, J., Jeffery, L.E., Kaur, S., Briggs, Z., et al. (2011). Trans-endocy-Immtosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of
CTLA-4. Science 332, 600–603.
Reinhardt, R.L., Liang, H.E., and Locksley, R.M. (2009). Cytokine-secreting
follicular T cells shape the antibody repertoire. Nat. Immunol. 10, 385–393.
Sage, P.T., Francisco, L.M., Carman, C.V., and Sharpe, A.H. (2013). The re-
ceptor PD-1 controls follicular regulatory T cells in the lymph nodes and blood.
Nat. Immunol. 14, 152–161.
Sakaguchi, S., Yamaguchi, T., Nomura, T., and Ono, M. (2008). Regulatory
T cells and immune tolerance. Cell 133, 775–787.
Salek-Ardakani, S., Choi, Y.S., Rafii-El-Idrissi Benhnia, M., Flynn, R., Arens, R.,
Shoenberger, S., Crotty, S., Croft, M., and Salek-Ardakani, S. (2011). B cell-
specific expression of B7-2 is required for follicular Th cell function in response
to vaccinia virus. J. Immunol. 186, 5294–5303.
Shevach, E.M. (2009). Mechanisms of foxp3+ T regulatory cell-mediated sup-
pression. Immunity 30, 636–645.
Tian, L., Altin, J.A., Makaroff, L.E., Franckaert, D., Cook,M.C., Goodnow, C.C.,
Dooley, J., and Liston, A. (2011). Foxp3+ regulatory T cells exert asymmetric
control over murine helper responses by inducing Th2 cell apoptosis. Blood
118, 1845–1853.
Vaeth, M., Mu¨ller, G., Stauss, D., Dietz, L., Klein-Hessling, S., Serfling, E., Lipp,
M., Berberich, I., and Berberich-Siebelt, F. (2014). Follicular regulatory T cells
control humoral autoimmunity via NFAT2-regulated CXCR5 expression.
J. Exp. Med. 211, 545–561.
Vendetti, S., Davidson, T.S., Veglia, F., Riccomi, A., Negri, D.R., Lindstedt, R.,
Pasquali, P., Shevach, E.M., and De Magistris, M.T. (2010). Polyclonal Treg
cells enhance the activity of a mucosal adjuvant. Immunol. Cell Biol. 88,
698–706.
Vijayanand, P., Seumois, G., Simpson, L.J., Abdul-Wajid, S., Baumjohann, D.,
Panduro, M., Huang, X., Interlandi, J., Djuretic, I.M., Brown, D.R., et al. (2012).
Interleukin-4 production by follicular helper T cells requires the conserved Il4
enhancer hypersensitivity site V. Immunity 36, 175–187.
Walker, L.S., Gulbranson-Judge, A., Flynn, S., Brocker, T., Raykundalia, C.,
Goodall, M., Fo¨rster, R., Lipp, M., and Lane, P. (1999). Compromised OX40
function in CD28-deficient mice is linked with failure to develop CXC chemo-
kine receptor 5-positive CD4 cells and germinal centers. J. Exp. Med. 190,
1115–1122.
Walker, L.S., Wiggett, H.E., Gaspal, F.M., Raykundalia, C.R., Goodall, M.D.,
Toellner, K.M., and Lane, P.J. (2003). Established T cell-driven germinal center
B cell proliferation is independent of CD28 signaling but is tightly regulated
through CTLA-4. J. Immunol. 170, 91–98.
Wang, C.J., Kenefeck, R., Wardzinski, L., Attridge, K., Manzotti, C., Schmidt,
E.M., Qureshi, O.S., Sansom, D.M., andWalker, L.S. (2012). Cutting edge: cell-
extrinsic immune regulation by CTLA-4 expressed on conventional T cells.
J. Immunol. 189, 1118–1122.
Wildin, R.S., Ramsdell, F., Peake, J., Faravelli, F., Casanova, J.L., Buist, N.,
Levy-Lahad, E., Mazzella, M., Goulet, O., Perroni, L., et al. (2001). X-linked
neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the
human equivalent of mouse scurfy. Nat. Genet. 27, 18–20.
Wildin, R.S., Smyk-Pearson, S., and Filipovich, A.H. (2002). Clinical andmolec-
ular features of the immunodysregulation, polyendocrinopathy, enteropathy, X
linked (IPEX) syndrome. J. Med. Genet. 39, 537–545.
Wing, K., and Sakaguchi, S. (2010). Regulatory T cells exert checks and bal-
ances on self tolerance and autoimmunity. Nat. Immunol. 11, 7–13.
Wing, J.B., and Sakaguchi, S. (2014). Foxp3+ T(reg) cells in humoral immunity.
Int. Immunol. 26, 61–69.
Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z.,
Nomura, T., and Sakaguchi, S. (2008). CTLA-4 control over Foxp3+ regulatory
T cell function. Science 322, 271–275.
Wollenberg, I., Agua-Doce, A., Herna´ndez, A., Almeida, C., Oliveira, V.G., Faro,
J., and Graca, L. (2011). Regulation of the germinal center reaction by Foxp3+
follicular regulatory T cells. J. Immunol. 187, 4553–4560.
Yamaguchi, T., Wing, J.B., and Sakaguchi, S. (2011). Two modes of immune
suppression by Foxp3(+) regulatory T cells under inflammatory or non-inflam-
matory conditions. Semin. Immunol. 23, 424–430.unity 41, 1013–1025, December 18, 2014 ª2014 Elsevier Inc. 1025
